Vertex Pharmaceuticals Incorporated (VRTX) earnings
VRTX earnings moved a median of -0.07% by the close. Quarterly and annual VRTX reports and results, each read against the price at its own news timestamp. Back to the VRTX overview →
30 measured VRTX earnings events.
Where these VRTX earnings landedvs 30 measured VRTX earnings reactions
| Middle 50% of VRTX earnings reactions | -1.10% to +1.27% |
|---|---|
| Median reaction (to close) | -0.07% |
| Measured reactions | 30 |
Point-in-time · zero look-ahead
Half of the 30 VRTX earnings events with a measured close landed between -1.10% and +1.27%; 50% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Vertex to Announce Third Quarter 2026 Financial Results November 2nd | Press release | -0.24% | +0.02% | |
| Form 10-Q VERTEX PHARMACEUTICALS For: Jun 30 | SEC filing · Form 10-Q | -0.19% | -0.55% | |
| Vertex Reports Second Quarter 2026 Financial Results | Press release | +2.12% | +1.57% | |
| Vertex to Announce Second Quarter 2026 Financial Results on August 3rd | Press release | +0.12% | -4.71% | |
| Form 10-Q VERTEX PHARMACEUTICALS For: Mar 31 | SEC filing · Form 10-Q | +0.41% | +1.08% | |
| Vertex Reports First Quarter 2026 Financial Results | Press release | -2.12% | -2.20% | |
| Vertex to Announce First Quarter 2026 Financial Results on May 4th | Press release | -1.29% | -0.84% | |
| Form 10-K VERTEX PHARMACEUTICALS For: Dec 31 | SEC filing · Form 10-K | -0.98% | -2.48% | |
| Form 10-Q VERTEX PHARMACEUTICALS For: Sep 30 | SEC filing · Form 10-Q | -0.36% | -0.17% | |
| Vertex Reports Third Quarter 2025 Financial Results | Press release | -1.28% | +1.59% | |
| Vertex to Announce Third Quarter 2025 Financial Results on November 3rd | Press release | +1.01% | +2.35% | |
| Form 10-Q VERTEX PHARMACEUTICALS For: Jun 30 | SEC filing · Form 10-Q | +0.17% | +2.63% | |
| Vertex Reports Second Quarter 2025 Financial Results | Press release | -2.30% | -8.40% | |
| Vertex to Announce Second Quarter 2025 Financial Results on August 4th | Press release | +0.72% | +2.32% | |
| Form 10-Q VERTEX PHARMACEUTICALS For: Mar 31 | SEC filing · Form 10-Q | -1.44% | -2.84% | |
| Vertex Reports First Quarter 2025 Financial Results | Press release | -2.96% | -2.95% | |
| Vertex to Announce First Quarter 2025 Financial Results on May 5th | Press release | +1.07% | -1.01% | |
| Form 10-K VERTEX PHARMACEUTICALS For: Dec 31 | SEC filing · Form 10-K | +0.72% | -0.76% | |
| Form 10-Q VERTEX PHARMACEUTICALS For: Sep 30 | SEC filing · Form 10-Q | -2.61% | -2.32% | |
| Vertex Reports Third Quarter 2024 Financial Results | Press release | -1.21% | +3.50% | |
| Vertex to Announce Third Quarter 2024 Financial Results on November 4th | Press release | -0.32% | +0.67% | |
| Form 10-Q VERTEX PHARMACEUTICALS For: Jun 30 | SEC filing · Form 10-Q | +0.61% | +1.36% | |
| Vertex Reports Second Quarter 2024 Financial Results | Press release | +2.19% | +0.60% | |
| Vertex to Announce Second Quarter 2024 Financial Results on August 1 | Press release | -0.02% | +0.86% | |
| Form 10-Q VERTEX PHARMACEUTICALS For: Mar 31 | SEC filing · Form 10-Q | +0.40% | +1.33% | |
| Vertex Reports First Quarter 2024 Financial Results | Press release | -1.33% | +0.94% | |
| Vertex to Announce First Quarter 2024 Financial Results on May 6 | Press release | -0.22% | -0.58% | |
| Form 10-K VERTEX PHARMACEUTICALS For: Dec 31 | SEC filing · Form 10-K | -0.63% | -1.13% | |
| Form 10-Q VERTEX PHARMACEUTICALS For: Sep 30 | SEC filing · Form 10-Q | -0.95% | -1.00% | |
| Vertex Reports Third Quarter 2023 Financial Results | Press release | -1.31% | +0.23% |
Keep exploring
More VRTX: analyst actions → · SEC filings → · VRTX overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| CESCA THERAPEUTICS INC COMMON (KOOL) | 736 | -0.01% | 37% |
| AIMMUNE THERAPEUTICS (AIMT) | 734 | -0.29% | 40% |
| AbbVie Inc. (ABBV) | 731 | 0.00% | 50% |
| INSYS THERAPEUTICS (INSY) | 731 | +0.00% | 50% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.